Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Safety, Tolerability and Pharmacokinetics of Single Rising Doses of YF476, a Gastrin Antagonist, in Healthy Men

This study has been completed.
Ferring Pharmaceuticals
Information provided by (Responsible Party):
Trio Medicines Ltd. Identifier:
First received: February 15, 2012
Last updated: February 20, 2012
Last verified: February 2012

The objectives of the study were:

  • To assess the safety, tolerability and pharmacokinetics of YF476 in healthy volunteers.
  • To select a dose or doses of YF476 for detailed pharmacodynamic studies in healthy volunteers.

Condition Intervention Phase
Reflux Oesophagitis
Drug: YF476
Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double Blind (Participant, Investigator)
Primary Purpose: Basic Science
Official Title: A Double-blind, Placebo-controlled Study to Assess the Safety, Tolerability and Pharmacokinetics of Single Rising Oral Doses of YF476, a Novel, Potent and Selective Gastrin/Cholecystokinin-B Antagonist, in Healthy Male Volunteers

Further study details as provided by Trio Medicines Ltd.:

Primary Outcome Measures:
  • Clinically relevant changes from baseline in safety assessments [ Time Frame: 6 weeks ]
    Physical examination, ECG and safety tests of blood and urine at screening and at 24 hours and 7 days after dosing. ECG, blood pressure and heart rate during study period.

  • Numbers of adverse events [ Time Frame: 6 weeks ]
    Adverse events during study period and at follow-up.

  • Pharmacokinetic parameters: Cmax, Tmax, AUC 0-24 h, T1/2 [ Time Frame: 6 weeks ]

    Blood samples (10 mL) for assay of YF476 at 0, 0.25, 0.5, 0.75, 1.0, 1.5, 2, 3, 4, 5, 6, 8, 10, 12 and 24 hours after dosing.

    Urine collection: 0-6, 6-12 and 12-24 hours after dosing.

Enrollment: 15
Study Start Date: May 1996
Study Completion Date: June 1996
Primary Completion Date: June 1996 (Final data collection date for primary outcome measure)
Intervention Details:
    Drug: YF476

    Two groups of six subjects received single rising oral doses of YF476 capsules or matching placebo. Each subject received 2 doses of YF476 and 1 dose of placebo. 4 subjects received active and 2 placebo at each dose level, as follows:

    Group A YF476 0.5, 25 and 100mg by mouth Group B YF476 5.0, 50 and 100mg by mouth

    Groups A & B were dosed alternately, at weekly intervals

Detailed Description:
YF476 is clearly a potent and selective gastrin/CCK-B antagonist and should inhibit basal and meal-stimulated gastric acid secretion and enhance gastric emptying of a liquid meal in man. Therefore YF476 might benefit patients with reflux oesophagitis. The compound has been remarkably well tolerated in animal toxicity studies at doses well in excess of the projected therapeutic dose in patients, and merits first administration to healthy volunteers. That study using the oral route of administration is described here. Extrapolation from data obtained with pentagastrin in animals suggest that single doses of less than 1mg of YF476 should be active in man. However, extrapolation from data obtained in comparative studies with the H2-antagonists and with omeprazole in animals suggest that the therapeutic dose in patients with reflux oesophagitis will be larger, in the region of 10mg. A range of single doses will be used in this study. The maximum dose will be 10 times more than the expected therapeutic dose.

Ages Eligible for Study:   18 Years to 45 Years   (Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Male and aged 18-45 years.
  • No clinically relevant abnormal findings in the clinical history or physical examination at the screening assessment which could interfere with the objectives of the study or make the subject's participation hazardous.
  • No clinically relevant abnormal laboratory values at the screening evaluation (Attachment 2).
  • A normal ECG at the screening examination.
  • A body mass index (Quetelet index) in the range 19-30:
  • Body Mass Index = weight [kg]_ height [m]2
  • Normal blood pressure and heart rate at the screening examination, i.e. BP 90-150mmHg systolic, 40-95mmHg diastolic; heart rate 40-100 beats/min in seated position.
  • Subjects must be of sufficient intelligence to understand the nature of the study and any hazards of their participation in it. They must be able to communicate satisfactorily with the Investigator and to participate in, and comply with the requirements of, the entire study.
  • Subjects must give their written consent to participate after reading the Information-for-Volunteers Leaflet and Consent Form, and after having the opportunity to discuss the study with the Investigator or his deputy.

Exclusion Criteria:

  • Clinically relevant abnormal history or physical findings at the screening assessment, which could interfere with the objectives of the study or the safety of the subject's participation.
  • Clinically relevant abnormalities of laboratory values or ECG at screening evaluation.
  • Presence of acute or chronic illness or history of chronic illness sufficient to invalidate subject's participation in the study or make it unnecessarily hazardous.
  • Impaired endocrine, thyroid, hepatic, respiratory or renal function, diabetes mellitus, coronary heart disease or history of any psychotic mental illness.
  • Participation in other clinical studies of a new chemical entity or a prescription medicine within the previous 3 months.
  • Presence or history of drug or alcohol abuse, or intake of more than 40 units of alcohol weekly.
  • Loss of more than 400ml blood during the 3 months before the study, e.g. as a blood donor.
  • Use of prescription medication during 30 days before the study.
  • Use of an over-the-counter medicine during 7 days before the study
  • Blood pressure or heart rate outside those values specified under inclusion criterion (f).
  • Possibility that the subject will not cooperate with the requirements of the protocol.
  • Evidence of drug abuse on urine testing at study entry.
  • Positive test for hepatitis B or C or HIV 1 & 2.
  • High risk of hepatitis or HIV infection.
  • History of severe allergic disease.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01538784

United Kingdom
Hammersmith Medicines Research
London, United Kingdom, NW10 7EW
Sponsors and Collaborators
Trio Medicines Ltd.
Ferring Pharmaceuticals
Study Director: Malcolm J Boyce, FRCP FFPM Trio Medicines Limited
  More Information

Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Trio Medicines Ltd. Identifier: NCT01538784     History of Changes
Other Study ID Numbers: 96-001
Study First Received: February 15, 2012
Last Updated: February 20, 2012

Keywords provided by Trio Medicines Ltd.:
gastrin receptor antagonist
gastric pH
healthy subjects

Additional relevant MeSH terms:
Esophagitis, Peptic
Esophageal Diseases
Gastrointestinal Diseases
Digestive System Diseases
Peptic Ulcer
Duodenal Diseases
Intestinal Diseases
Stomach Diseases
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs processed this record on April 26, 2017